Results per Page:
Patients’ own autoantibodies may hold key to boosting cancer immunotherapy response
A study published in Nature finds that some cancer patients can make their “own companion drug,” suggesting a potential template for future treatments
Fred Hutch Cancer Center announces 2025 Evergreen Fund awardees
Nine Fred Hutch researchers receive funding totaling $1.175 million for projects with commercial partnership potential
Dr. Lawrence Fong, new Fred Hutch immunotherapy director, talks about how the field has transformed oncology
In-house grant funding program will underpin efforts to advance therapies to clinical trials
The New Yorker spotlights Fred Hutch’s pioneering cancer research
‘The Promise and Price of Cellular Therapies’ by Siddhartha Mukherjee traces journey from bone marrow transplantation to immunotherapy
Learning more from T-cell therapy trials
Fred Hutch Immunotherapy Integrated Research Center awards grants to Drs. Brian Till, Cameron Turtle
New insights into CAR T-cell therapy's potential side effects
Detailed study of cytokine release syndrome and neurologic toxicities could help make emerging cancer immunotherapies safer
6 things to know about glioblastoma
Following Sen. John McCain’s diagnosis, Fred Hutch experts offer ‘the long view’ on brain cancer research
Introducing new Therapeutics Products Program Director Dr. Bruce Thompson
‘Our goal is to be a world-leading provider of clinical products that cure cancer’
Good News: Bezos family funding accelerates glioma immunotherapy research
Celebrating faculty and staff achievements
5 researchers receive awards to explore immunotherapy single-cell RNA sequencing
Projects accelerate Hutch position as early adopter of scRNA-seq technology